Virtual Screening of FDA-Approved Drugs against Triose Phosphate Isomerase from <i>Entamoeba histolytica</i> and <i>Giardia lamblia</i> Identifies Inhibitors of Their Trophozoite Growth Phase

Virtual Screening of FDA-Approved Drugs against Triose Phosphate Isomerase from <i>Entamoeba histolytica</i> and <i>Giardia lamblia</i> Identifies Inhibitors of Their Trophozoite Growth Phase

Infectious diseases caused by intestinal protozoan, such as <i>Entamoeba histolytica</i> (<i>E. histolytica</i>) and <i>Giardia lamblia</i> (<i>G. lamblia</i>) are a worldwide public health issue. They affect more than 70 million people every year. The...

Full description

Bibliographic Details
Main Authors: Alfredo Juárez-Saldivar, Elizabeth Barbosa-Cabrera, Edgar E. Lara-Ramírez, Alma D. Paz-González, Ana V. Martínez-Vázquez, Virgilio Bocanegra-García, Isidro Palos, Nuria E. Campillo, Gildardo Rivera
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:International Journal of Molecular Sciences
Subjects:
protozoa
FDA
virtual screening
drug repositioning
molecular docking
Online Access:https://www.mdpi.com/1422-0067/22/11/5943

Similar Items

Similar Items